Replies to post #65800 on Amarin Corp Plc (AMRN)

[ziploc_1]

On slide 3:....."CV outcomes results expected 2018,POTENTIALLY 2016"
I would have said:....CV outcome results EXPECTED 2016, potentially 2018.... but then, I would not have to answer to a swarm of lawyers if it does not work out to be 2016.

[sts66]

Thanks for the link - looks like I owe BioChica a mea culpa - according to slide 5, patient population for ANCHOR is 36M, but R-IT, patients with TGs 150-199, adds another 34M people - doubles addressable population - that's huge. Guess I just forgot! <sheepish grin>

Also answers a question that's been floating around here - they ARE promoting JELIS:

Broader Opportunity via Court Decision: declaratory judgment in August 2015 allows for education of physicians regarding ANCHOR trial results

? Now allowed to communicate more data to physicians, including results of ANCHOR and JELIS trials, subject to disclaimers

Slide 18 is entirely devoted to CHERRY study! Odd that diluted share count on slide 19 is 244M - they aren't counting convertible debt owned by the BB's like HDG does.